Document is current
Any future updates will be listed below
-
Authors
Iaconis, Daniela http://orcid.org/0000-0002-1052-6634
Bordi, Licia
Matusali, Giulia
Talarico, Carmine
Manelfi, Candida
Cesta, Maria Candida http://orcid.org/0000-0002-4847-2985
Zippoli, Mara
Caccuri, Francesca
Bugatti, Antonella
Zani, Alberto
Filippini, Federica
Scorzolini, Laura
Gobbi, Marco http://orcid.org/0000-0003-1014-6225
Beeg, Marten
Piotti, Arianna
Montopoli, Monica
Cocetta, Veronica
Bressan, Silvia
Bucci, Enrico M.
Caruso, Arnaldo http://orcid.org/0000-0001-5178-566X
Nicastri, Emanuele
Allegretti, Marcello http://orcid.org/0000-0002-0617-0233
Beccari, Andrea R.
- License Information
-
More Information
Article History
Received: 13 December 2021
Revised: 12 May 2022
Accepted: 17 May 2022
First Online: 25 May 2022
Competing interests
: The authors MA, MCC, MZ, CT, DI, CM, ARB are permanent employees of Dompé farmaceutici s.p.a. coordinator of the Horizon 2020 European project “N.101003551-EXSCALATE4CoV”, and sponsor of the running clinical trial conducted with raloxifene in COVID-19 patients. The authors EN, LB, GM and LS are employees of L. Spallanzani National Institute for Infectious Disease, IRCCS, Rome. The authors EMB, FC, AB, AZ, FF, MG, MB, AP, MM, VC, SB, and AC declare no competing interests.
